Vollständige Version anzeigen : Nastech Pharmaceutical
Rente mit 30
25-06-2001, 19:29
Interessanter Artikel im Anlegerbrief.
Ob das der neue Blockbuster wird?
Hi Rente,
ich dachte, du treibst dich nur noch im Chat rum.
Rente mit 30
25-06-2001, 23:08
Hi Kollege,
das ist ein technischer Fehler, keine Ahnung warum ich da ständig drin bin.
Nastech heute + knapp 9 %. Denke ein Rückschlag auf um die 7 sollte charttechnisch drin sein. Ob die 5 - 5,5 allerdings kommen, bezweifle ich. Schade dass die Umsätze in D so gering sind.
Gruss
Rm30
Rente mit 30
29-06-2001, 18:25
11,60 Euro, nicht schelcht, aber der Chart weist einen Widerstand auf.
euroinvest
01-07-2001, 23:02
Nicht schlecht. Wenn der Kurs bisschen zurück kommen sollte, kaufe ich auch.
Daume hoch für Anlegerbrief http://www.stockboard.de/ubb/smile.gif
@ all
Der Anlegerbrief ist aber nicht der erste der Nastech entdeckt hat. Habe Nastech schon ein paar Wochen im Depot!
Schaut Euch mal den Link an, bisschen Infos zu Nastech der das gewaltige Potenzial zeigen soll:
http://www.the-bulls.de/r.php?i=117&n=1
Der Kursverlauf sollte sich bald wie der von Osi Pharma. Medarex oder Medimmune entwickeln.
Predo
Wednesday July 18, 9:18 am Eastern Time
Press Release
SOURCE: Nastech Pharmaceutical Company Inc.
Successful Delivery of Apomorphine to the Brain Following Intranasal Administration Demonstrated in Clinical Study
New Approach to Treatment of Central Nervous System Diseases Bypasses the Blood - Brain - Barrier
HAUPPAUGE, N.Y., July 18 /PRNewswire/ -- Nastech Pharmaceutical Company Inc. (Nasdaq: NSTK - news) announced today that it has demonstrated the preferential uptake of intranasally administered Apomorphine directly into the cerebral spinal fluid (CSF), a fluid that surrounds and supports the brain and spinal cord. The nasal delivery of pharmaceutically active compounds that are not able to cross the blood-brain-barrier when given by other routes of administration may provide a new, non-invasive way of treating Alzheimer's disease, Parkinson's disease, stroke and other important brain diseases and conditions.
The study, which was initiated in May, was conducted as a Phase I, single dose, open label clinical trial in 12 healthy male subjects at SUNY Stony Brook Medical Center in Stony Brook, New York. Apomorphine was administered intranasally to each subject, and thereafter blood was drawn, and CSF samples were obtained by spinal tap. Apomorphine levels were determined by HPLC-MS- MS, a state-of-the-art analytical tool. The results were expressed as a ratio of CSF level to blood level at various times indicated. The data indicate that Nastech's intranasal Apomorphine HCl formulation produced a CSF to plasma ratio of 0.27 to 0.44 at 20 minutes. This can be compared to a ratio of less than 0.05 resulting from the subcutaneous administration of Apomorphine under the same experimental conditions as noted in published clinical studies. No significant adverse events were observed during the study.
The results of the clinical study are promising because distribution of drugs to the brain tissue is highly restricted even though the brain receives approximately 20% of cardiac output. Drugs normally reach the central nervous system (CNS) via two mechanisms: the brain capillaries and the CSF. The endothelial cells of the brain's capillaries, which appear to be more tightly joined to one another than are those of other capillaries, contribute to the fact that many drugs enter the brain slowly or not at all. In addition to the restrictive capillary walls, there are also connective tissue cells that form an astrocyte sheath close to the basement membrane of the capillary endothelium. Together the capillary walls and the astrocytic sheath form what is commonly referred to as the blood-brain-barrier. The results of the clinical study indicate that certain drugs via nasal administration may be deposited directly into the CSF, bypassing the blood-brain-barrier.
``We are pleased by the results of this clinical study, which confirms that nasal drug delivery, unlike other drug delivery modalities, provides a unique pathway for drug molecules to reach the brain,'' stated Steven C. Quay, M.D., Ph.D., Chairman, President and Chief Executive Officer of Nastech. ``We intend to expand our internal research programs and the breadth of our therapeutic focus to include intranasal delivery of drugs to potentially treat major diseases of the central nervous system, such as Parkinson's, Alzheimer's and Multiple Sclerosis. We also believe this provides unique intellectual property opportunities that should enhance Nastech's valuable patent estate.''
Nastech Pharmaceutical Company Inc., recognized worldwide as a leader in nasal drug delivery technology, is dedicated to improving patient care by using ``Formulation Science'', a systematic approach to drug development using biophysics, physical chemistry, and pharmacology to maximize therapeutic efficacy and safety, and provide new therapeutic options. Additional information on Nastech is available at http://www.Nastech.com.
Nastech Safe Harbor Statement
Statements contained herein that are not historical fact may be forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, that are subject to a variety of risks and uncertainties. There are a number of important factors that could cause actual results to differ materially from those projected or suggested in any forward-looking statement made by the Company. These factors include, but are not limited to: (i) the Company's ability to successfully complete product research and development, including pre-clinical and clinical studies and commercialization; (ii) the Company's ability to obtain required governmental approvals, including product and patent approvals; (iii) the Company's ability to attract and/or maintain manufacturing, sales, distribution and marketing partners; and (iv) the Company's ability to develop and commercialize its products before its competitors. In addition, significant fluctuations in quarterly results may occur as a result of varying milestone payments and the timing of costs and expenses related to the Company's research and development program. Additional factors that would cause actual results to differ materially from those projected or suggested in any forward-looking statements are contained in the Company's filings with the Securities and Exchange Commission, including those factors discussed under the caption ``Risk Factors'' in the Company's most recent Annual Report on Form 10-K.
Stelle heute mal einen Alltimechart von Nastech rein!
Wer Anfang 2000 eingestiegen ist hat schon die halbe Miete rein auf dem Weg zum Millionär.
Seit 2000 ein solider Aufwärtstrend.
<IMG SRC="http://chart.yahoo.com/c/my/n/nstk.gif" border=0>
Nastech Demonstrates Successful Delivery of Intranasal Interferon In Man
HAUPPAUGE, N.Y., July 26 /PRNewswire/ -- Nastech Pharmaceutical Company Inc. (Nasdaq: NSTK - news) today announced results from a Phase I pharmacokinetic safety and tolerance study in the United States demonstrating therapeutic blood levels of intranasally administered interferon alpha. The clinical study data is being presented today at the 6th International Drug Delivery Technologies & Deal Making Summit in Princeton, New Jersey.
The single dose, open-label study, involving 12 healthy male volunteers ages 18 to 50, was conducted at Nastech's clinical research unit at Stony Brook Medical Center in Stony Brook, New York. The data reported today involves doses of 3, 6, and 12 million International Units (MIU). The subjects were tested at various time intervals, with maximum therapeutic blood levels achieved at approximately three hours post dosing. Using standard formulation components typical of nasal products, interferon alpha blood levels were not detected. However, applying Nastech's proprietary formulations, intranasal interferon alpha achieved similar blood levels to the marketed product administered subcutaneously at three hours post dosing. The formulations were well tolerated, and no nasal irritation was observed during the study.
``This study establishes a significant breakthrough in the delivery of therapeutic proteins,'' stated Steven C. Quay, M.D., Ph.D., Chairman, President and Chief Executive Officer of Nastech. ``Intranasal interferon alpha may provide the first non-invasive, easy-to-use alternative for patients who are taking interferon alpha for the treatment of hepatitis B and C and certain cancers including hairy cell leukemia, malignant melanoma, follicular lymphoma, condylomata acuminata, and AIDS-related Kaposi's Sarcoma. We believe this is the first time a molecule of this size has been successfully delivered nasally in human clinical trials. The possibility now exists for the nasal delivery of other therapeutic proteins with a molecular weight of up to 20,000 Daltons.''
Nastech intends to conduct additional formulation studies with various interferon products, including PEG versions, and to seek a collaborative alliance for this product. The Company also plans to expand its research programs to include other proteins of significant molecular weight.
Interferons are a family of glycoproteins derived from human cells that normally have a role in fighting viral infections by preventing virus replication in cells. In recent years, interferons have increasingly been studied for applications in treating a host of major diseases. Interferon alpha is indicated for the treatment of certain forms of cancer and hepatitis. SG Cowen estimates that worldwide sales of interferon alpha for certain indications could expand from approximately $1.2 billion in 2000 to $3.8 - 4.0 billion in 2004, with Schering-Plough having a 75 percent market share, and Roche Pharmaceuticals having a 25 percent market share.
The medical literature suggests that continuous IV administration of interferon alpha to patients with hepatitis may permit the use of a lower dose, with subsequent lowering of significant drug related side effects. Since continuous infusion outside the hospital setting is impractical, administration via the nasal route may allow one to achieve blood levels similar to those from a continuous IV administration, with the accrued benefits, including improved patient-to-patient dose variability. In many patients with significant chronic diseases, weight-loss, with accompanying loss of skeletal muscle and subcutaneous tissue depots, makes drug injection an unusually painful, less reliable route of administration.
Nastech Pharmaceutical Company Inc., recognized worldwide as a leader in nasal drug delivery technology, is dedicated to improving patient care by using ``Formulation Science,'' a systematic approach to drug development using biophysics, physical chemistry, and pharmacology to maximize therapeutic efficacy and safety, and provide new therapeutic options. Additional information on Nastech is available at http://www.Nastech.com.
Nastech Safe Harbor Statement
Statements contained herein that are not historical fact may be forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, that are subject to a variety of risks and uncertainties. There are a number of important factors that could cause actual results to differ materially from those projected or suggested in any forward-looking statement made by the Company. These factors include, but are not limited to: (i) the Company's ability to successfully complete product research and development, including pre-clinical and clinical studies and commercialization; (ii) the Company's ability to obtain required governmental approvals, including product and patent approvals; (iii) the Company's ability to attract and/or maintain manufacturing, sales, distribution and marketing partners; and (iv) the Company's ability to develop and commercialize its products before its competitors. In addition, significant fluctuations in quarterly results may occur as a result of varying milestone payments and the timing of costs and expenses related to the Company's research and development program. Additional factors that would cause actual results to differ materially from those projected or suggested in any forward-looking statements are contained in the Company's filings with the Securities and Exchange Commission, including those factors discussed under the caption ``Risk Factors'' in the Company's most recent Annual Report on Form 10-K.
Wednesday September 26, 11:51 am Eastern Time
CORRECTED - Nastech licenses intranasal morphine rights
In NEW YORK story headlined ``Nastech licenses intranasal morphine rights'' please read in the third paragraph ``...efforts in the European market,'' instead of ``...efforts in the EU market.'' (Company corrects statement to clarify the agreement covers all of Europe, not just the European Union).
A corrected repetition follows:
NEW YORK, Sept 26 (Reuters) - Nastech Pharmaceutical Inc. (NasdaqNM:NSTK - news) on Wednesday said it had licensed rights for commercialization in Europe of its intranasal morphine treatment to privately held G. Pohl Boskamp GmbH & Co. of Germany.
Morphine is the most commonly used opioid to control severe pain. In its intranasal form, it is absorbed directly into circulation, bypassing problems that occur with oral administration like the removal of therapeutic quantities from the bloodstream by gastrointestinal and liver metabolism, Nastech said.
``Under terms of the agreement, Pohl-Boskamp will also complete the balance of the development program necessary for commercializing the product in Europe and have full responsibility for all manufacturing, sales and marketing efforts in the European market,'' the company said.
Nastech shares were up 3.5 percent at $8.02 Wednesday mid-morning on Nasdaq.
Wednesday November 7, 10:30 am Eastern Time
Press Release
SOURCE: Nastech Pharmaceutical Company Inc.
Nastech and University of Pennsylvania Initiate Research Collaboration for Alzheimer's Disease Treatment
HAUPPAUGE, N.Y., Nov. 7 /PRNewswire/ -- Nastech Pharmaceutical Company Inc. (Nasdaq: NSTK - news) announced today a research collaboration with the Center for Neurodegenerative Disease Research (CNDR) at the University of Pennsylvania to explore the potential of its nasally administered beta-sheet breakers in inhibiting or reversing the formation of brain plaque associated with Alzheimer's Disease (AD). This research endeavor was unveiled to world leaders in Alzheimer's Disease research at the CNDR's 2nd Annual Retreat on Emerging Alzheimer's Disease Therapies by co-founders and co-directors John Q. Trojanowski, M.D., Ph.D. and Dr. Virginia M.-Y. Lee, Ph.D.
``Our approach has the potential to significantly improve the current standard of care for AD and other brain diseases as well,'' said Steven C. Quay, M.D., Ph.D., Chairman, President, and Chief Executive Officer of Nastech. ``Nastech's proven intranasal administration technology is moving us towards this goal by allowing our proprietary formulations to be delivered directly into the cerebral spinal fluid, representing a breakthrough in AD treatment.''
The two-year research program focuses on the in vitro and in vivo assessment of Nastech's intranasal dosage forms of novel small molecules in stopping or reversing the beta stacking of the amyloid and Tau proteins. In particular, genetic, neuropathologic and biochemical evidence now indicates that the deposition of insoluble proteins, including amyloid as well as Tau, in the brain plays an important role in the development and progression of dementia in AD. Nastech will provide its compounds to CNDR and fund the research with the goal of determining their potential for human clinical development. Nastech will retain commercialization rights to all data generated from the research program.
``Our collaboration with Nastech is the first step in what we hope will be a major step forward in AD research,'' said Dr. Trojanowski. ``Most beta-sheet breakers have an extremely short half-life and poor blood-brain barrier penetration. We believe that intranasal administration of Nastech's beta- sheet breakers will overcome these limitations by enabling direct delivery to the brain via the olfactory pathway, where there is no blood-brain barrier.''
For unknown reasons, in the brain of the Alzheimer's patients, the amyloid protein implicated in AD folds into a particular secondary structure called beta-sheet conformation. The beta-sheet conformation of the amyloid protein is highly insoluble and aggregates to form fibrils and plaques. The mechanism by which senile plaques and vascular amyloid are associated with symptoms of Alzheimer's disease is unknown. However, several studies have shown that beta-amyloid fibrils are neurotoxic. Beta-sheet breakers mimic the region of the amyloid protein that regulates stacking. They stop the beta stacking of the amyloid protein, thus inhibiting plaque formation.
About Alzheimer's Disease
Alzheimer's disease (AD) is an age-related and irreversible brain disorder that occurs gradually and results in memory loss, behavior and personality changes, and a decline in thinking abilities. These losses are related to the breakdown of the connections between nerve cells in the brain and the eventual death of many of these cells. The course of this disease varies from person to person, as does the rate of decline. On average, patients with AD live for 8 to 10 years after they are diagnosed, though the disease can last for up to 20 years.
AD is the most common cause of dementia among people age 65 and older. It presents a major health problem for the United States because of its enormous impact on individuals, families, the health care system, and society as a whole. Scientists estimate that up to 4 million people currently suffer with the disease, and the number of people with the disease at one time doubles every 5 years beyond age 65. It is also estimated that approximately 360,000 new cases will occur each year and that this number will increase as the population ages.
About CNDR
CNDR was founded in 1991 and was awarded a grant from the National Institute on Aging (NIA) of the National Institutes of Health (NIH) to establish the first and only NIH-funded Alzheimer Disease Center in the Delaware Valley, part of a network of 27 cooperating NIH-funded Centers throughout the nation. John Q. Trojanowski M.D., Ph.D., and Virginia M.-Y. Lee, Ph.D. established and are co-directors of CNDR. Together, they lead a team of over 35 University of Pennsylvania researchers, including Penn undergraduates, School of Medicine graduate students, postdoctoral fellows, technicians, and research associates. CNDR researchers and their network of collaborators within and outside Penn work on a variety of projects that are funded by several NIH and foundation grants to CNDR. Additional information on CNDR is available at http://www.uphs.upenn.edu/cndr/.
About Nastech
Nastech Pharmaceutical Company Inc., recognized worldwide as a leader in nasal drug delivery technology, is dedicated to improving patient care by using ``Formulation Science'', a systematic approach to drug development using biophysics, physical chemistry, and pharmacology to maximize therapeutic efficacy and safety, and provide new therapeutic options. Additional information on Nastech is available at http://www.Nastech.com.
Nastech Safe Harbor Statement
Statements contained herein that are not historical fact may be forward- looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, that are subject to a variety of risks and uncertainties. There are a number of important factors that could cause actual results to differ materially from those projected or suggested in any forward-looking statement made by the Company. These factors include, but are not limited to: (i) the Company's ability to successfully complete product research and development, including pre-clinical and clinical studies and commercialization; (ii) the Company's ability to obtain required governmental approvals, including product and patent approvals; (iii) the Company's ability to attract and/or maintain manufacturing, sales, distribution and marketing partners; and (iv) the Company's ability to develop and commercialize its products before its competitors. In addition, significant fluctuations in quarterly results may occur as a result of varying milestone payments and the timing of costs and expenses related to the Company's research and development program. Additional factors that would cause actual results to differ materially from those projected or suggested in any forward-looking statements are contained in the Company's filings with the Securities and Exchange Commission, including those factors discussed under the caption ``Risk Factors'' in the Company's most recent Annual Report on Form 10-K.
Thursday December 13, 7:00 am Eastern Time
Press Release
SOURCE: Nastech Pharmaceutical Company Inc.
Nastech Announces Positive Results from Phase II Clinical Trial of Nasally Administered Apomorphine for Erectile Dysfunction
~ With Efficacy Over 80% as Measured 15 Minutes After Dosing, The Product May Offer Better Alternative in the ED Patient Population ~
HAUPPAUGE, N.Y., Dec. 13 /PRNewswire/ -- Nastech Pharmaceutical Company Inc. (Nasdaq: NSTK - news) reported today the results of a Phase II clinical trial in 184 men with erectile dysfunction (ED) that concluded its nasally administered apomorphine formulation demonstrated excellent efficacy, was well tolerated with minimal side effects, and has an onset of action, about 15 minutes after dosing, that uniquely matches normal human sexual response physiology. The study supports the final stages of the clinical development of the product and Nastech expects the pivotal Phase III trials to begin early next year.
``These results support our belief that nasally administered apomorphine may be an attractive alternative to the PDE-5 inhibitor class of therapies in the treatment of erectile dysfunction, and thus represents a significant commercial opportunity to address the multi-billion dollar worldwide ED market,'' said Steven C. Quay, M.D., Ph.D., Chairman, President and Chief Executive Officer of Nastech. ``We are currently in negotiations to complete a worldwide development and marketing agreement for this product and we believe the results of this study strongly support these commercialization efforts.''
SITE OF ACTION
Normal human sexual response begins with sensory input to the brain. The focus of this ``central'' input is the hypothalamus, a region of the brain that, among other functions, controls erectile function via nerves from the brain via the spinal cord to blood vessels in the penile tissue. Apomorphine is a potent dopamine agonist that promotes erectile function by stimulating receptors in the hypothalamus. The PDE-5 inhibitor class of ED therapies does not function in the brain but only on the final step in erectile function. In addition, unlike the class of PDE-5 inhibitors that produce hypotension, headaches, and other side effects due to non-specific interactions in the body, apomorphine acts specifically on the D1/D2 class of dopamine receptors that are responsible for the initiation of the erectile response in the brain. Nastech's nasally administered formulation is the subject of numerous patent applications in the U.S., European Union countries, Japan, and other major countries.
TIME OF ONSET
Prior pharmacokinetic trials indicated that nasally administered apomorphine has a maximum blood level about 15 minutes after dosing and also appears in the cerebral spinal fluid at high levels within 20 minutes after administration. Therefore, this trial was designed to obtain efficacy data 15 minutes after dosing. Research begun in the 1950s by Masters and Johnson and others demonstrate that this time of onset coincides with normal human sexual response physiology.
EFFICACY
The study involved men up to 75 years of age with ED of all etiologies (50% psychogenic, 26% mixed organic, and 24% diabetic) and severities (64% were moderate or severe at baseline as judged by the IIEF domain score). There were no patient restrictions as to prior use of ED medications nor was pre-qualification with use of a RigiScan® (indicative of mild erectile dysfunction) needed for inclusion in the study. The men were randomly placed in four dosage groups: placebo, 0.25 mg, 0.50 mg, and 1.0 mg apomorphine with treatment consisting of up to 18 doses and efficacy recorded after every administration and after every eight doses using validated ED efficacy questionnaires. The treatment group demographics were not different with respect to age (mean of 56 to 60 years), ethnicity, ED etiology, or ED severity.
The ability to achieve some erection was found in 81%, 89%, and 91% of the men treated with 0.25 mg, 0.50 mg, and 1.0 mg nasally administered apomorphine, respectively. With respect to erections sufficient for vaginal penetration, 69%, 73%, and 82% of men reported success in the three-apomorphine dosage groups compared to 35% for the placebo group (1.0 mg vs. placebo, p < 0.0001). Nasally administered apomorphine compared to placebo also demonstrated statistically significant improvements in erectile function (including erection sufficient to complete sexual intercourse with ejaculation), confidence in erection, orgasmic function, and intercourse satisfaction.
SAFETY
No significant adverse events were reported among the 184 patients enrolled in the study. Side effects were infrequent, mild to moderate in intensity, of short duration, and resolved without intervention. Side effects above 1% were unusual taste (5%) and dizziness (3%). There were no reported instances of hypotension, syncope or pre-syncopal events, including vomiting, sweating, flushing or vasodilatation, hot flashes, or pallor.
ERECTILE DYSFUNCTION
ED is defined as the inability to achieve and/or maintain an erection adequate for satisfactory sexual function. Approximately 30 million men in the U.S. and 150 million men worldwide suffer from ED (Deutsche Banc Alex. Brown, June 2001). The ED market is expected to have peak sales of over six billion dollars worldwide. The condition is correlated with increasing age, cardiovascular disease, hypertension, diabetes, hyperlipidemia and smoking. In addition, neurogenic risk factors such as radical prostatectomy, spinal cord injury and multiple sclerosis, certain prescription drugs, and psychogenic issues may contribute to ED. The U.S. market for nasally administered apomorphine for ED treatment, based on the product profile achieved in the At Home Phase II Study reported here, is forecast to achieve peak sales of over $850 million (Defined Health, December 2001). See Safe Harbor Statement below concerning these forward-looking statements.
FEMALE SEXUAL DYSFUNCTION
In addition to developing nasally administered apomorphine for treatment of ED, Nastech is currently conducting a randomized, double blind, placebo-controlled Phase II clinical trial in approximately 75 women suffering from female sexual dysfunction (FSD). The study is designed to assess the safety and efficacy of nasally administered apomorphine in increasing sexual satisfaction in women.
NASTECH CONFERENCE CALL AND WEBCAST - TODAY
Management will discuss Nastech's Phase II Apomorphine data during a conference call, which will be broadcast live over the Internet, at 11 a.m. EST today, December 13, 2001. To access the call, please dial: 1-800-592-3872. The reservation number is 20095307. In conjunction with Nastech's conference call, you are invited to listen to its conference call and view an on-line slide presentation that will be simultaneously broadcast live over the Internet at: http://www.videonewswire.com/event.asp?id=2434.
ABOUT NASTECH
Nastech Pharmaceutical Company Inc., recognized worldwide as a leader in nasal drug delivery technology, is dedicated to improving patient care by using ``Formulation Science,'' a systematic approach to drug development using biophysics, physical chemistry, and pharmacology to maximize therapeutic efficacy and safety, and provide new therapeutic options. Additional information on Nastech is available at http://www.Nastech.com.
NASTECH SAFE HARBOR STATEMENT
Statements contained herein that are not historical fact may be forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, that are subject to a variety of risks and uncertainties. Total market size projections reported herein were obtained from third parties and are forward-looking statements. Apomorphine market size projections reported herein were contained in a study commissioned and paid for by the Company and are forward-looking statements. Furthermore, the Company has performed no independent verification of these forward-looking statements. There are a number of important factors that could cause actual results to differ materially from those projected or suggested in any forward-looking statement made by the Company. These factors include, but are not limited to: (i) the Company's ability to successfully complete product research and development, including pre-clinical and clinical studies and commercialization; (ii) the Company's ability to obtain required governmental approvals, including product and patent approvals; (iii) the Company's ability to attract and/or maintain manufacturing, sales, distribution and marketing partners; and (iv) the Company's ability to develop and commercialize its products before its competitors. In addition, significant fluctuations in quarterly results may occur as a result of varying milestone payments and the timing of costs and expenses related to the Company's research and development program. Additional factors that would cause actual results to differ materially from those projected or suggested in any forward-looking statements are contained in the Company's filings with the Securities and Exchange Commission, including those factors discussed under the caption ``Risk Factors'' in the Company's most recent Annual Report on Form 10-K.
Contact: Matthew D. Haines
Director, Corporate Communications
(631) 273-0101, ext. 329
mhaines@nastech.com
Noonan/Russo Communications
(212) 696-4455
Ellie Kline, ext. 254 (media)
David Walsey, ext. 230 (investors)
SOURCE: Nastech Pharmaceutical Company Inc.
Es wird immer spanneder mi Nastech, langsam werden immer mehr Erfolge vermeldet und viele Investoren endecken Nastech.
Den Artikel gibts in der aktuellen TOP-GEWINN-Ausgabe.
Nastech wandelt Medikamente in Spraydosen um:
Viagra aus der Spraydose
Wer in der boomenden Pharma-industrie nach einem echten Geheimtipp sucht, könnte sich das US-Spezialunternehmen Nastech Pharmaceuticals ansehen.
Von Michael Kordovsky
Der neue Hauptaktionär und CEO Dr. Steven Quay verwandelte den kleinen Generika-Spezialisten aus Long Island in einen bedeutenden Formulation-Science-Partner, der Substanzen und Medikamente als Nasensprays klinisch testet.
In den kommenden Monaten sollten noch Sprays gegen Parkinson und Alzheimer ins klinische Testprogramm aufgenommen werden. Doch das bisher größte Ereignis der Firmengeschichte könnte sich noch vor Jahresende ereignen. Der von Nastech entwickelte Potenzspray soll an einen Pharmakonzern lizensiert werden, und Upfront-Zahlungen in der Größenordnung von bis zu fünf Millionen US-Dollar würden dann neue Impulse im laufenden Neurologie-Programm geben.
Die Tragweite dieses Ereignisses ist enorm. Sollte es der Apomorphin-Spray nämlich bis zur Zulassung schaffen, könnte Viagra zugunsten dieser neuen Lifestyle-Droge Marktanteile verlieren, denn der Markt für Potenzmittel liegt weltweit bei ca. eineinhalb Milliarden US-Dollar.
Hi Nastech Fans!
Der CFO von Nastech wird Ende des Jahres das Unternehmen verlassen, was das für Auswirkungen für Nastech und den Aktienkurs hat vermag ich nicht einzuschätzen.
Aber kehren neue Besen, bekanntlich nicht besser als die alten?
Gibt es denn hier keinen außer mir der sich für diese kleine Perle interessiert?
Thursday December 20, 5:43 pm Eastern Time
Nastech Pharmaceutical's CFO Zinzi stepping down
HAUPPAUGE, N.Y., Dec 20 (Reuters) - Nasal drug specialist Nastech Pharmaceutical Co. Inc. (NasdaqNM:NSTK - news) said on Thursday that Chief Financial Officer Andrew Zinzi will resign effective Dec. 31.
He is leaving to pursue other interests, but will provide consulting services to the company until a successor is found.
``We appreciate all that Andy has undertaken in his five years at Nastech and I personally appreciate his willingness to work with me through the transition in leadership that has occurred since August 2000,'' said Steven Quay, chairman, president and chief executive.
Hi Leute!
Und wieder mal gute News von Nastech.
Tuesday January 8, 7:30 am Eastern Time
Press Release
SOURCE: Nastech Pharmaceutical Company Inc.
FDA Clears New Patented Test for Rapid Identification Of Breast Cancer Risk Factors
Nastech Intends for Non-Invasive Test to Become Adjunct to Mammography And Physical Examination in Breast Disease Detection and Management
HAUPPAUGE, N.Y., Jan. 8 /PRNewswire/ -- Nastech Pharmaceutical Company Inc. (Nasdaq: NSTK - news) announced today that it has received clearance from the U.S. Food and Drug Administration (FDA) to market its non-invasive, patented Mammary Aspiration Specimen Cytology Test (MASCT) device for potential early detection of breast cancer.
The device was developed with the goal of better enabling physicians to detect atypical changes in cells lining the milk ducts -- the location where an estimated 95 percent of all breast cancers originate. Nastech anticipates the MASCT will eventually become an adjunct to current standards of medical care, which include mammography and clinical breast exams.
Results from a clinical trial of healthy, non-pregnant, non-lactating, pre-menopausal female subjects, from 30 to 49 years of age, showed that the MASCT device produces results that correlate with mammogram and clinical breast exam results. In particular, the MASCT device successfully collected diagnostic amounts of Nipple Aspirate Fluid (NAF) for a conclusive cytological examination. No adverse events were reported.
``The MASCT device and kit is an important and valuable company asset with heightened commercial potential based on recent business transactions in the area of breast cancer risk assessment devices and scientific breakthroughs on the utility of mammary aspirate specimens in predicting breast cancer risk,'' stated Steven C. Quay, M.D., Ph.D., Chairman, President and Chief Executive Officer. ``Nastech is now ready to initiate the next phase of the commercialization process for the product, which we obtained as part of the acquisition of Atossa HealthCare.''
Nastech anticipates that its proprietary device will allow physicians to enhance breast cancer testing and compliance among patients at a lower cost than currently available options. It is anticipated that most women ages 20 and over may seek the MAS cytology test at the same time as a PAP smear test.
The device also received a United States patent on September 11, 2001. The patent, number 6,287,521, is entitled, ``Methods and devices for obtaining and assaying mammary fluid samples for evaluating breast diseases, including cancer,'' and contains broad claims directed to a sample collection device for obtaining mammary aspirate specimens.
ABOUT MAMMARY ASPIRATE SPECIMENS AND BREAST CANCER RISK
The medical rationale for mammary aspiration is compelling since a number of investigators, including the inventor of the Pap smear, Dr. George Papanicolaou, have published studies demonstrating that high-risk women with atypical milk duct cells have a significantly increased, near-term risk of developing breast cancer:
-- Breast Cancer and Breast Fluid Link: For almost three decades,
academic investigators have investigated the relationship of breast
fluid characteristics, obtained from non-lactating women by non-
invasive means, with the development of benign and malignant breast
diseases. Using epidemiological techniques to link cytology changes
to the incidence of breast disease, a correlation has been found which
links increased risk of developing breast diseases with abnormal
cellular pathology.
-- Large Scale Clinical Support: A recent study (Wrensch MR, et al.,
Breast Cancer Risk in Women with Abnormal Cytology in Nipple Aspirates
of Breast Fluid, J. National Cancer Institute, 93:1791-1798, 2001)
involved a combined cohort of 7673 women, with a median age of 43
years at study initiation, who were studied for 21 years (n=4046) and
9 years (n=3627), respectively. The studies involved obtaining
mammary aspirate specimens, classifying the most severe epithelial
cytology observed in fluid samples, and determining breast cancer
incidence. The women were free of breast cancer at baseline and had
not developed the disease within 6 months of study entry. The study
concluded that women with abnormal cytology in mammary aspirate
specimens have an increased risk of breast cancer. The authors
conclude by supporting the use of this technique to identify high-risk
patients, to investigate and understand breast cancer pathogenesis,
and to evaluate the efficacy of new chemopreventive agents against
breast cancer and benign breast disease.
-- An Addition to Mammographic Screening: In addition, a research letter
by Evron and colleagues, published in the April 27, 2001 issue of The
Lancet, reported that cells collected from breast ducts can be tested
for potential molecular breast cancer markers using
methylation-specific PCR (MSP). The authors concluded, "Carrying out
MSP in these fluid samples may provide a sensitive and powerful
addition to mammographic screening for early detection of breast
cancer."
FACTS ABOUT BREAST CANCER: According to a report from the National Cancer Institute (NCI), breast cancer is the most common form of cancer among women, excluding non-melanoma skin cancers. About one in eight women in the United States will develop breast cancer during her lifetime. This year, an estimated 192,200 women will learn they have invasive breast cancer and 40,200 women will die from the disease. More than 85 million American women ages 20 and over are candidates for breast cancer screening. ACS and the National Comprehensive Cancer Network currently recommend annual mammograms for women identified as normal risk beginning at age 40 and for women identified as high-risk beginning at age 25.
ABOUT NASTECH
Nastech Pharmaceutical Company Inc., recognized worldwide as a leader in nasal drug delivery technology, is dedicated to improving patient care by using ``Formulation Science,'' a systematic approach to drug development using biophysics, physical chemistry, and pharmacology to maximize therapeutic efficacy and safety, and provide new therapeutic options. Additional information on Nastech is available at www.Nastech.com. (http://www.Nastech.com.)
NASTECH SAFE HARBOR STATEMENT
Statements contained herein that are not historical fact may be forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, that are subject to a variety of risks and uncertainties. There are a number of important factors that could cause actual results to differ materially from those projected or suggested in any forward-looking statement made by the Company. These factors include, but are not limited to: (i) the Company's ability to successfully complete product research and development, including pre-clinical and clinical studies and commercialization; (ii) the Company's ability to obtain required governmental approvals, including product and patent approvals; (iii) the Company's ability to attract and/or maintain manufacturing, sales, distribution and marketing partners; and (iv) the Company's ability to develop and commercialize its products before its competitors. In addition, significant fluctuations in quarterly results may occur as a result of varying milestone payments and the timing of costs and expenses related to the Company's research and development program. Additional factors that would cause actual results to differ materially from those projected or suggested in any forward-looking statements are contained in the Company's filings with the Securities and Exchange Commission, including those factors discussed under the caption ``Risk Factors'' in the Company's most recent Annual Report on Form 10-K.
Contact:
Matthew D. Haines
Director, Corporate Communications
(631) 273-0101, ext. 329
mhaines@nastech.com
Noonan/Russo Communications
(212) 696-4455
Ellie Kline, ext. 254 (media)
David Walsey, ext. 230 (investors)
SOURCE: Nastech Pharmaceutical Company Inc.
Wednesday January 23, 2:00 am Eastern Time
Press Release
SOURCE: Nastech Pharmaceutical Company Inc.
Nastech Receives Approval to Market Nascobal(R) in Sweden
Regulatory Submissions in Other EU Countries Planned
HAUPPAUGE, N.Y., Jan. 23 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical Company Inc. (Nasdaq: NSTK - news) announced today that the Swedish Medical Products Agency (MPA) has granted marketing authorization for the sale of Nascobal® (Cyanocobalamin USP) Gel for Intranasal Administration to treat Vitamin B12 malabsorption. Nastech intends to market the product through a European licensee.
``Regulatory approval in Sweden is an important first step in opening up the European market for Nascobal,'' stated Steven C. Quay, M.D., Ph.D., Chairman, President and Chief Executive Officer of Nastech. ``Now that we have received marketing authorization in the Reference Member State, Sweden, we intend to secure additional regulatory approvals in other EU countries through the mutual recognition process.''
Vitamin B12 deficiency often results from dietary deficiencies in strict vegetarians, structural or functional damage to the gastrointestinal tract (Crohn's Disease, colitis), certain cancer chemotherapy drug therapies, certain antiviral drug therapies, certain drug therapies for the treatment of acid reflux and Gastroesophageal Reflux Disease, or GERD, and chronic conditions such as pernicious anemia. Patients requiring more than the normal amount of Vitamin B12 due to pregnancy, hepatic or renal disease are also at increased risk.
Nascobal is currently marketed in the U.S. through Nastech's U.S. licensee, Schwarz Pharma. Prior to the U.S. introduction of Nascobal, patients with vitamin B12 deficiency were routinely treated with injectable therapy or inadequately treated with oral tablets. Such therapies involve issues related to insufficient absorption of oral B12, poor patient compliance, painful injections, variable blood levels of Vitamin B12 and cost restrictions.
ABOUT NASTECH
Nastech Pharmaceutical Company Inc., recognized worldwide as a leader in nasal drug delivery technology, is dedicated to improving patient care by using ``Formulation Science,'' a systematic approach to drug development using biophysics, physical chemistry, and pharmacology to maximize therapeutic efficacy and safety, and provide new therapeutic options. Additional information on Nastech is available at www.Nastech.com. (http://www.Nastech.com.)
NASTECH SAFE HARBOR STATEMENT
Statements contained herein that are not historical fact may be forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, that are subject to a variety of risks and uncertainties. There are a number of important factors that could cause actual results to differ materially from those projected or suggested in any forward-looking statement made by the Company. These factors include, but are not limited to: (i) the Company's ability to successfully complete product research and development, including pre-clinical and clinical studies and commercialization; (ii) the Company's ability to obtain required governmental approvals, including product and patent approvals; (iii) the Company's ability to attract and/or maintain manufacturing, sales, distribution and marketing partners; and (iv) the Company's ability to develop and commercialize its products before its competitors. In addition, significant fluctuations in quarterly results may occur as a result of varying milestone payments and the timing of costs and expenses related to the Company's research and development program. Additional factors that would cause actual results to differ materially from those projected or suggested in any forward-looking statements are contained in the Company's filings with the Securities and Exchange Commission, including those factors discussed under the caption ``Risk Factors'' in the Company's most recent Annual Report on Form 10-K.
Contact: Matthew D. Haines
Director, Corporate Communications
(631) 273-0101, ext. 329
mhaines@nastech.com
Noonan/Russo Communications
(212) 696-4455
Ellie Kline, ext. 254 (media)
David Walsey, ext. 230 (investors)
SOURCE: Nastech Pharmaceutical Company Inc.
Thursday January 31, 9:32 am Eastern Time
Press Release
SOURCE: Emerald Asset Management
Nastech to Present at Emerald Investment Forum
LANCASTER, Pa.--(BUSINESS WIRE)--Jan. 31, 2002--Nastech to present at Emerald Forum: Emerald Asset Management has announced thatNastech Pharmaceutical Company, Inc. (NASDAQ - NSTK) will be presenting at the Ninth Annual Emerald Groundhog Day Investment Forum, scheduled for Tuesday, February 5, 2002 at the Wyndham Franklin Plaza Hotel in Philadelphia.
The Forum will again showcase investment opportunities in some of the region's fastest growing companies, as well as industry leaders from across the country. Senior management of over forty companies are scheduled to make 30-minute formal presentations during concurrent sessions. The Forum is presented by Emerald Asset Management, Inc. and its subsidiaries.
This year's Forum addresses the challenges and opportunities of the post-September 11th investment environment and will feature themes such as life sciences, consumer goods and emerging technology, as well as all-day focuses on private companies, hosted by Emerald Venture Capital, and on banking and financial services companies.
Emerald will be providing an audio feed of the entire Forum via their Internet website at www.teamemerald.com/ (http://www.teamemerald.com/) All company presentations will be broadcast live and will be available for replay following the conference.
Headquartered in Lancaster, Pennsylvania with satellite offices in King of Prussia, Pittsburgh and San Diego, California, Emerald Asset Management is a diversified investment services company whose subsidiaries include Emerald Advisers, Inc., Emerald Venture Capital and the Emerald Mutual Funds, offering research-driven investment products and services to retail, institutional and private/alternative investors.
Additional Forum and Emerald Research information, including registration information, can be found on Emerald's Internet home page at http://www.teamemerald.com/
--------------------------------------------------------------------------------
Contact:
Nastech
by
Emerald Research
Milzy Carrasco, 717/396-1116
Monday February 4, 7:00 am Eastern Time
Press Release
SOURCE: Nastech Pharmaceutical Company Inc.
Nastech and Pharmacia Reach Worldwide Agreement To Develop and Market Nasally Administered Apomorphine
HAUPPAUGE, N.Y. and PEAPACK, N.J., Feb. 4 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical Company Inc. (Nasdaq: NSTK - news) and Pharmacia Corporation (NYSE: PHA - news) announced today an agreement for the development and marketing of Nastech's proprietary nasally administered apomorphine product for the treatment of erectile dysfunction (ED) and female sexual dysfunction (FSD).
Apomorphine is a potent dopamine agonist that promotes erectile function by stimulating the D1/D2 class of dopamine receptors in the brain that are responsible for the initiation of the erectile response. Nastech's proprietary nasal formulation is designed to maximize the rapid onset, therapeutic effect and overall safety of apomorphine.
Under terms of the agreement, Pharmacia receives exclusive, worldwide rights to develop and market nasally administered apomorphine for the treatment of male and female sexual dysfunction and will manage and fund all future development in these indications. Nastech retains certain development rights in other therapeutic areas.
Nastech will receive an upfront payment at signing of $3.0 million and, upon satisfaction of certain future conditions, development and sales milestones totaling an additional $45.0 million. Certain additional costs incurred by Nastech of up to $3.4 million are reimbursable. Less than half of the milestone payments will be based on achievement of certain sales levels. Pharmacia will also purchase 250,000 shares of Nastech common stock for $5.0 million.
Upon commercialization, Nastech will receive significant royalties on product sales that escalate based on sales levels. For the first five years following launch, Nastech will manufacture certain quantities of nasally administered apomorphine and will receive transfer payments from Pharmacia. Nastech also receives minimum royalties during a portion of the term of the agreement.
Nastech has conducted Phase II safety and efficacy studies in men with ED and is currently conducting a Phase II study in women with FSD.
``Pharmacia is the ideal partner for our nasally administered apomorphine product because of their outstanding drug development capabilities that require simultaneous worldwide coordination, exceptional marketing capabilities that require patient as well as physician education, and a strong competitive position in the rapidly expanding sexual dysfunction and urology markets worldwide,'' stated Steven C. Quay, M.D., Ph.D., Chairman, President and Chief Executive Officer of Nastech. ``This agreement allows Nastech to further expand our growing R&D pipeline of major product opportunities and thus represents an important validation of our new business model. As a leading formulation science company, we will continue to focus on the rapid and cost-effective early clinical development of proprietary nasal formulations of drugs, including morphine, a triptan, alpha interferon, beta interferon and human growth hormone which are already in clinical trials, with the goal of licensing these opportunities to leading pharmaceutical companies for significant upfront, milestone, and royalty payments.''
``We are very pleased that Nastech has chosen Pharmacia for the development and marketing of nasally administered apomorphine,'' said Goran Ando, M.D., Executive Vice President and President, Research and Development, Pharmacia Corporation. ``This drug candidate represents an innovative approach to the treatment of sexual dysfunction where we have an established research, development and commercial presence.''
The transaction is subject to a number of conditions to closing set forth in the agreement, including making necessary antitrust filings and expiration or early termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 as amended.
NASTECH CONFERENCE CALL AND WEBCAST - TODAY
Management will discuss Nastech's agreement with Pharmacia during a conference call today, February 4, 2002, at 10:00 a.m. EST. The public is invited to access the call via a live audio webcast at: http://asp01sea.activate.net/intercall/noonan/jan/registration/default.asp.
A telephone replay of the conference call will also be available from approximately 1:00 p.m. (EST) today through February 6, 2002. To access the replay of the conference call, United States and Canadian participants should call (800) 642-1687. International participants should call (706) 645-9291. The Conference ID number is 3157165.
ABOUT PHARMACIA
Pharmacia Corporation is a top-tier global pharmaceutical company with a leading agricultural subsidiary. Pharmacia's innovative medicines and other products save lives and enhance health and wellness. Pharmacia's 59,000 people work together with many diverse stakeholders to bring these benefits to people around the world, and to create new health solutions for the future.
ABOUT NASTECH
Nastech Pharmaceutical Company Inc., recognized worldwide as a leader in nasal drug delivery technology, is dedicated to improving patient care by using ``Formulation Science,'' a systematic approach to drug development using biophysics, physical chemistry, and pharmacology to maximize therapeutic efficacy and safety, and provide new therapeutic options. Additional information on Nastech is available at www.nastech.com. (http://www.nastech.com.)
NASTECH SAFE HARBOR STATEMENT
Statements contained herein that are not historical fact may be forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, that are subject to a variety of risks and uncertainties. There are a number of important factors that could cause actual results to differ materially from those projected or suggested in any forward-looking statement made by the Company. These factors include, but are not limited to: (i) the Company's ability to successfully complete product research and development, including pre-clinical and clinical studies and commercialization; (ii) the Company's ability to obtain required governmental approvals, including product and patent approvals; (iii) the Company's ability to attract and/or maintain manufacturing, sales, distribution and marketing partners; and (iv) the Company's ability to develop and commercialize its products before its competitors. In addition, significant fluctuations in quarterly results may occur as a result of varying milestone payments and the timing of costs and expenses related to the Company's research and development program. Additional factors that would cause actual results to differ materially from those projected or suggested in any forward-looking statements are contained in the Company's filings with the Securities and Exchange Commission, including those factors discussed under the caption ``Risk Factors'' in the Company's most recent Annual Report on Form 10-K.
PHARMACIA SAFE HARBOR STATEMENT
This press release contains forward-looking or anticipatory statements about Pharmacia's business and financial performance which are based on the information currently available and the expectations currently deemed reasonable by Pharmacia. However, because these forward-looking statements are subject to many risks, uncertainties and changes over time, including those referenced in Pharmacia's filings with the U.S. Securities and Exchange Commission, actual results may differ materially from those expressed or implied by these forward-looking statements. Pharmacia undertakes no obligation to update any forward-looking statements as a result of new information or future developments.
NOTE TO EDITORS
Erectile Dysfunction (ED) is the inability to achieve and/or maintain an erection adequate for satisfactory sexual function. The condition is correlated with increasing age, cardiovascular disease, hypertension, diabetes, hyperlipidemia and smoking. In addition, neurogenic risk factors such as radical prostatectomy, spinal cord injury and multiple sclerosis, certain prescription drugs, and psychogenic issues may contribute to ED. An estimated 30 million men in the U.S. and 150 million men worldwide currently suffer from erectile dysfunction. This category is expected to achieve peak sales of over six billion dollars worldwide (Deutsche Banc Alex. Brown, June 2001). Currently, the only approved PDE-5 inhibitor is selling about $1.4 billion per year worldwide with a 30% annual growth rate.
Contact for Nastech: Contact for Pharmacia:
Matthew D. Haines Paul Fitzhenry (media)
Director, Corporate Communications (908) 901-8770
(631) 273-0101, ext. 329 Linda Heller (investors)
mhaines@nastech.com (908) 901-8853
Noonan/Russo Communications
(212) 696-4455
Ellie Kline, ext. 254 (media)
David Walsey, ext. 230 (investors)
SOURCE: Nastech Pharmaceutical Company Inc.
Hi Leute!
Hat denn keiner außer mir noch Nastech Aktien im Depot? :( Meldet euch doch mal und postet eure Meinungen zu diesem ausichtreichen Wert! ;)
Predo
Wednesday May 22, 10:01 am Eastern Time
Press Release
SOURCE: Nastech Pharmaceutical Company Inc.
Nastech Reports Positive Pre-Clinical Data on Alzheimer's Disease Research Program
- Acetylcholine Esterase Inhibitor Being Assessed for Direct-to-Brain Delivery By Intranasal Administration -
BOTHELL, Wash., May 22 /PRNewswire-FirstCall/ -- Steven C. Quay, M.D., Ph.D., Chairman, President, and Chief Executive Officer of Nastech Pharmaceutical Company Inc. (Nasdaq: NSTK - News), presented pre-clinical data from the Company's intranasal Acetylcholine Esterase inhibitor (AChE-I) research program at yesterday's Second Annual Panel Discussion on Alzheimer's Disease hosted by Cold Spring Harbor Laboratory. In particular, the intranasal delivery of the emerging AChE-I therapy known as NP-7557 was shown to maintain effective plasma and cerebral spinal fluid concentrations at significantly lower doses than the oral equivalent for the treatment of Alzheimer's disease.
The pre-clinical data suggests that intranasal NP-7557 may have the potential to benefit millions of patients afflicted with the age-related and irreversible brain disorder. Concentration of the drug through nasal delivery was 7-fold higher at 30 minutes and 2.5-fold higher at 60 minutes than oral AChE-I. In addition, this direct central nervous system delivery may enhance therapy benefits by eliminating cholinergic side effects in the GI tract and avoiding metabolism of the drug in the liver. Following successful completion of additional pre-clinical trials, Nastech will further explore NP-7557 in human studies anticipated to begin in 2003.
"Medical science acknowledges that Alzheimer's disease may result from a variety of physiological factors, and new treatment approaches must be equally complex in battling the disease," stated Dr. Quay, "We believe our work involving intranasal NP-7557 lays a solid foundation for more focused treatment of this devastating disease."
The U.S. Food and Drug Administration (FDA) has approved four Acetylcholine Esterase inhibitors to treat Alzheimer's disease, including Aricept (donepezil), Exelon (rivastigmine), Reminyl (galantamine) and Cognex (tacrine). Each of these treatments is directed to increasing the concentration of acetylcholine, a chemical found to be reduced in the brains of individuals with Alzheimer's disease. Acetylcholine helps to increase communication between nerve cells, and in turn, temporarily improves the symptoms of the disease. While these medicines are not a cure for Alzheimer's disease, they do help improve cognition and manage symptoms.
Alzheimer's Disease (AD) occurs gradually and results in memory loss, behavior and personality changes, and a decline in thinking abilities. These losses are related to the breakdown of the connections between nerve cells in the brain and the eventual death of many of these cells. The course of this disease varies from person to person, as does the rate of decline. On average, patients with AD live for 8 to 10 years after they are diagnosed, though the disease can last for up to 20 years.
AD is the most common cause of dementia among people age 65 and older. It presents a major health problem for the United States because of its enormous impact on individuals, families, the health care system, and society as a whole. Scientists estimate that up to 4 million people currently suffer with the disease, and the number of people with the disease at one time doubles every 5 years beyond age 65. It is also estimated that approximately 360,000 new cases will occur each year and that this number will increase as the population ages.
Nastech Pharmaceutical Company Inc., recognized as a leader in nasal drug delivery technology, is dedicated to improving patient care by using Formulation Science, a systematic approach to drug development using biophysics, physical chemistry, and pharmacology to maximize therapeutic efficacy and safety and provide new therapeutic options. Additional information on Nastech is available at http://www.Nastech.com .
Nastech Safe Harbor Statement
Statements contained herein that are not historical fact may be forward- looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, that are subject to a variety of risks and uncertainties. There are a number of important factors that could cause actual results to differ materially from those projected or suggested in any forward-looking statement made by the Company. These factors include, but are not limited to: (i) the Company's ability to successfully complete product research and development, including pre-clinical and clinical studies and commercialization; (ii) the Company's ability to obtain required governmental approvals, including product and patent approvals; (iii) the Company's ability to attract and/or maintain manufacturing, sales, distribution and marketing partners; and (iv) the Company's ability to develop and commercialize its products before its competitors. In addition, significant fluctuations in quarterly results may occur as a result of varying milestone payments and the timing of costs and expenses related to the Company's research and development program. Additional factors that would cause actual results to differ materially from those projected or suggested in any forward-looking statements are contained in the Company's filings with the Securities and Exchange Commission, including those factors discussed under the caption "Risk Factors" in the Company's most recent Annual Report on Form 10-K.
Contact: Matthew D. Haines
Director, Corporate Communications
(631) 273-0101, ext. 329
mhaines@nastech.com
Noonan Russo Presence Euro RSCG
(212) 696-4455
Glenn Silver, ext. 271 (media)
David Walsey, ext. 230 (investors)
SOURCE: Nastech Pharmaceutical Company Inc.
http://chart.yahoo.com/c/2y/n/nstk.gif
Nastech wird von Merck eine Bargeldzahlung von 5 Mio. $ erhalten.
Bei Erreichung von Meilensteinen (Entwicklungs-und Marketingvereinbarung bez. des Medikaments Peptide [Fettleibigkeit, Phase I]) winken weitere 131 Mio. $.
Bitte diese thread in den Biotech-Bereich verschieben! Danke! :)
csac1129
26-10-2004, 23:43
Hallo alle. Ich glaube aber dass NSTK wird korigieren. 1-2$ noch nach unten gehen und erst dann richtig ausbrechen. _Habt ihr die Nachricht von gestern gelesen? Es ist gut aber es tut sich nichts bei nstk.
Hi csac,
was macht dein LSBC- und DOR-Investment? Das Jahr ist bald rum... ;) :D
csac1129
27-10-2004, 00:04
Die Jahr ist noch nicht um oder? es gibt noxh Zeit. Ansonst zahle ich die Runde :)
Yep, 2 Monate haste noch die Dinger über $1 zu drücken! :D
Nastech bildet ein sym. Dreieck am oberen Ende seiner Konsolidierungszone aus!
Bei Ausbruch nach oben sind bei diesem Momementum-Monster mind. $18 prim. Downtrend) erreichbar.
http://bigcharts.marketwatch.com/charts/big.chart?symb=nstk&compidx=aaaaa%3A0&ma=1&maval=38%2C50%2C100%2C200&uf=0&lf=268435456&lf2=0&lf3=0&type=4&size=2&state=11&sid=3288&style=320&time=7&freq=1&comp=NO%5FSYMBOL%5FCHOSEN&nosettings=1&rand=7362&mocktick=1
Beware of the breakout 2morrow... ;)